Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 33Gastrointestinal 33Breast 13Gynecologic 11Head & Neck 9Other hematologic neoplasm 6Lymphoid 6Other solid neoplasm 5Tumor-Agnostic 4CNS 4Sarcoma 3Genitourinary 2Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 73Nivolumab 60Ipilimumab 38Specimen Handling 30Magnetic Resonance Spectroscopy 26Cyclophosphamide 23Biopsy 19cemiplimab 15Radiosurgery 14relatlimab 12fludarabine 12CTLA-4 Antigen 12binimetinib 11trametinib 9Opdualag 9Immunoglobulin G 9fludarabine phosphate 8avelumab 8Disulfides 8Blood Specimen Collection 8lifileucel 7encorafenib 7dabrafenib 7atezolizumab 7aldesleukin 7Radiotherapy 7Paclitaxel 7X-Rays 6Interleukin-2 6HhAntag691 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug Therapy × Dermatologic × 90 days × Clear all
NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡